Raya Therapeutic: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Raya Therapeutic
Largest movements
- Receivables within one year -€1,680
down €1,680 (-98.5%), from €1,707 to €26
of which Other amounts receivable: -€1,229
- Cash +€334
up €334 (+6.7%), from €4,970 to €5,303
mainly Other debts (+€9,815) and Receivables within one year (+€1,680)
- Other debts +€9,815
new in 2025: €9,815
- Trade debts -€7,159
down €7,159 (-82.9%), from €8,636 to €1,477
- Profit (loss) carried forward -€4,003
down €4,003 (-56.9%), from -€7,040 to -€11,043
- Gross operating margin +€3,216
up €3,216 (+46.4%), from -€6,933 to -€3,717
- Financial charges +€179
up €179 (+168%), from €107 to €286
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €6,676 | €5,330 | -€1,347 | -20.2% |
| Current assets | 29/58 | €6,676 | €5,330 | -€1,347 | -20.2% |
| Amounts receivable within one year | 40/41 | €1,707 | €26 | -€1,680 | -98.5% |
| Trade receivables | 40 | €451 | - | -€451 | |
| Other amounts receivable | 41 | €1,256 | €26 | -€1,229 | -97.9% |
| Cash at bank and in hand | 54/58 | €4,970 | €5,303 | +€334 | +6.7% |
| Total equity and liabilities | 10/49 | €6,676 | €5,330 | -€1,347 | -20.2% |
| Equity | 10/15 | -€1,959 | -€5,962 | -€4,003 | -204% |
| Contributions | 10/11 | €5,081 | €5,081 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€7,040 | -€11,043 | -€4,003 | -56.9% |
| Amounts payable | 17/49 | €8,636 | €11,292 | +€2,656 | +30.8% |
| Amounts payable within one year | 42/48 | €8,636 | €11,292 | +€2,656 | +30.8% |
| Trade debts | 44 | €8,636 | €1,477 | -€7,159 | -82.9% |
| Suppliers | 440/4 | €8,636 | €1,477 | -€7,159 | -82.9% |
| Other amounts payable | 47/48 | - | €9,815 | +€9,815 | |
| Gross operating margin | 9900 | -€6,933 | -€3,717 | +€3,216 | +46.4% |
| Operating profit (loss) | 9901 | -€6,933 | -€3,717 | +€3,216 | +46.4% |
| Financial charges | 65/66B | €107 | €286 | +€179 | +168% |
| Recurring financial charges | 65 | €107 | €286 | +€179 | +168% |
| Profit (loss) for the period before taxes | 9903 | -€7,040 | -€4,003 | +€3,037 | +43.1% |
| Profit (loss) for the period | 9904 | -€7,040 | -€4,003 | +€3,037 | +43.1% |
| Profit (loss) for the period to be appropriated | 9905 | -€7,040 | -€4,003 | +€3,037 | +43.1% |
Source: filed annual accounts (NBB), financial years ended 30 September 2024 and 30 September 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 October 2026 via checked.be.